Schizophrenia Trial, Recruiting NCT05142735 Sponsor: Centre for Addiction and Mental Health Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05142735
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who meet specific criteria for being at risk of developing psychosis, as assessed through a structured clinical interview called the SIPS.
  • People who are able to understand and agree to take part in the study on their own.
  • Women who are not able to become pregnant (for example, due to sterilisation or being post-menopausal for at least one year), OR women who are able to become pregnant and agree to use an approved form of contraception for the whole study.

Who may not be able to join:

  • People who currently have another diagnosable mental health condition (except a personality disorder, nicotine dependence, or a substance use disorder that is fully in remission).
  • People who have a current or past neurological condition (a condition affecting the brain or nervous system).
  • People who have uncorrected vision problems, or a history of a reading disability.
  • People who have previously been treated with antipsychotic medication at a full therapeutic dose.
  • People who are currently taking any psychiatric medication, unless it is an antidepressant that has been taken at a stable dose for at least 30 days.
  • People who are pregnant or intend to become pregnant.
  • People who are breastfeeding or plan to breastfeed.
  • People with a history of kidney stones.
  • People currently taking antibiotic medication.
  • People currently taking nitroglycerin medication.
  • People with a known allergy to any ingredient in the trial treatment or the placebo.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Kiang, MD, PhD, Centre for Addiction and Mental Health

Phone: 416-535-8501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre for Addiction and Mental Health
Registry
ClinicalTrials.gov
Start date
13 January 2023
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in positive psychosis-like symptoms from baseline to 8 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov